RU2015144309A3 - - Google Patents

Download PDF

Info

Publication number
RU2015144309A3
RU2015144309A3 RU2015144309A RU2015144309A RU2015144309A3 RU 2015144309 A3 RU2015144309 A3 RU 2015144309A3 RU 2015144309 A RU2015144309 A RU 2015144309A RU 2015144309 A RU2015144309 A RU 2015144309A RU 2015144309 A3 RU2015144309 A3 RU 2015144309A3
Authority
RU
Russia
Application number
RU2015144309A
Other languages
Russian (ru)
Other versions
RU2015144309A (ru
RU2742435C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015144309A publication Critical patent/RU2015144309A/ru
Publication of RU2015144309A3 publication Critical patent/RU2015144309A3/ru
Application granted granted Critical
Publication of RU2742435C2 publication Critical patent/RU2742435C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015144309A 2013-03-15 2014-03-06 Композиции промоторов RU2742435C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794818P 2013-03-15 2013-03-15
US61/794,818 2013-03-15
PCT/US2014/021357 WO2014149882A1 (en) 2013-03-15 2014-03-06 Promoter compositions

Publications (3)

Publication Number Publication Date
RU2015144309A RU2015144309A (ru) 2017-04-24
RU2015144309A3 true RU2015144309A3 (enExample) 2018-03-13
RU2742435C2 RU2742435C2 (ru) 2021-02-05

Family

ID=51580666

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015144309A RU2742435C2 (ru) 2013-03-15 2014-03-06 Композиции промоторов

Country Status (14)

Country Link
US (1) US10105450B2 (enExample)
EP (1) EP2970969B1 (enExample)
JP (1) JP6473438B2 (enExample)
KR (1) KR102332835B1 (enExample)
CN (1) CN105358690B (enExample)
AU (1) AU2014237759B2 (enExample)
BR (1) BR112015022885A2 (enExample)
CA (1) CA2906315C (enExample)
ES (1) ES2809479T3 (enExample)
IL (1) IL241667B (enExample)
MX (1) MX373848B (enExample)
RU (1) RU2742435C2 (enExample)
WO (1) WO2014149882A1 (enExample)
ZA (1) ZA201507439B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364369B (zh) 2012-05-02 2018-09-07 生命技术公司 哺乳动物细胞中使用独特的高密度生长和转染培养基与表达增强剂对的高产量瞬时表达

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7205146B1 (en) * 2000-06-14 2007-04-17 Oscient Pharmaceuticals Corporation Nucleotide and amino acid sequences relating to respiratory diseases and obesity
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
JP2004008216A (ja) 2002-03-22 2004-01-15 Research Association For Biotechnology 新規な全長cDNA
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2005237384A (ja) 2002-03-22 2005-09-08 Research Association For Biotechnology 新規な全長cDNA
EP1707640A1 (en) * 2005-04-01 2006-10-04 Leiden University Medical Centre (LUMC) acting on behalf of the Academic Hospital Leiden Method of screening for the presence of a genetic defect associated with deep venous thrombosis
ITRM20050475A1 (it) * 2005-09-19 2007-03-20 Univ Degli Studi Genova Sequenze trascritte da rna polimerasi iii tipo iii e loro uso.
AU2007254983A1 (en) 2006-05-31 2007-12-13 Orion Genomics Llc Gene methylation in cancer diagnosis
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
WO2008113773A2 (en) * 2007-03-16 2008-09-25 Biorigen S.R.L. Gene expression regulation technology and noncoding rnas for diagnosis and therapy
ES2334608B1 (es) * 2007-11-13 2011-01-24 Universidad Autonoma De Madrid Metodo para la identificacion de compuestos que inducen o inhiben estres de reticulo endoplasmatico o estres oxidativo.
EP2310525B1 (en) * 2008-07-09 2014-02-26 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods

Also Published As

Publication number Publication date
US20160022837A1 (en) 2016-01-28
CN105358690B (zh) 2019-12-31
HK1220486A1 (zh) 2017-05-05
CN105358690A (zh) 2016-02-24
EP2970969A4 (en) 2016-11-16
EP2970969B1 (en) 2020-05-06
RU2015144309A (ru) 2017-04-24
AU2014237759B2 (en) 2020-02-27
JP6473438B2 (ja) 2019-02-20
EP2970969A1 (en) 2016-01-20
ZA201507439B (en) 2022-03-30
BR112015022885A2 (pt) 2017-11-07
MX2015013036A (es) 2016-05-18
JP2016512028A (ja) 2016-04-25
KR20150129001A (ko) 2015-11-18
RU2742435C2 (ru) 2021-02-05
CA2906315A1 (en) 2014-09-25
AU2014237759A1 (en) 2015-10-22
ES2809479T3 (es) 2021-03-04
KR102332835B1 (ko) 2021-11-29
WO2014149882A1 (en) 2014-09-25
IL241667B (en) 2021-03-25
US10105450B2 (en) 2018-10-23
CA2906315C (en) 2022-12-13
MX373848B (es) 2020-03-26

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112016001515A2 (enExample)
BR112016001125A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014018502A2 (enExample)
BR112014018516A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014020341A2 (enExample)
BR112016012525A2 (enExample)
BR112014021878A2 (enExample)
BR112014018468A2 (enExample)
BR112014019204A2 (enExample)
BR112016005824A2 (enExample)
BR112016004849A2 (enExample)
BR112014017901A2 (enExample)
BR112014017745A2 (enExample)
BR112014018483A2 (enExample)
BR112016010966A2 (enExample)
BR112016004224A2 (enExample)
BR112014017722A2 (enExample)
BR112014017794A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)